Impact Factor 4.076

The 3rd most cited journal in Microbiology

Correction ARTICLE

Front. Microbiol., 09 November 2016 | https://doi.org/10.3389/fmicb.2016.01813

Corrigendum: Bacteriophage Procurement for Therapeutic Purposes

  • 1Bacteriophage Laboratory, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
  • 2Phage Therapy Unit, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
  • 3Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
  • 4Autonomous Department of Microbial Biology, Faculty of Agriculture and Biology, Warsaw University of Life Sciences, Warsaw, Poland
  • 5Department of Clinical Immunology, Transplantation Institute, Medical University of Warsaw, Warsaw, Poland

A corrigendum on
Bacteriophage Procurement for Therapeutic Purposes

by Weber-Dąbrowska, B., Jończyk-Matysiak, E., Żaczek, M., Łobocka, M. B., Łusiak-Szelachowska, M., and Górski, A. (2016). Front. Microbiol. 7:1177. doi: 10.3389/fmicb.2016.01177

In the original article, we neglected to include the Wrocław Centre of Biotechnology as a funding source. The full Funding statement should read as follows:

This work was financially supported by the project “Innovative Bacteriophage Preparation for the Treatment of Diabetic Foot” no. POIG.01.03.01-02-048/12 funded by the National Center for Research and Development. MŁ contribution was financially supported by the statutory funds for the Institute of Biochemistry and Biophysics, PAS. Publication was also supported by Wrocław Centre of Biotechnology, programme, the Leading National Research Centre (KNOW) for years 2014–2018.

The authors apologize for this oversight. This error does not change the scientific conclusions of the article in any way.

Conflict of Interest Statement

BW-D and AG are inventors of a patent (EP1 406 642 B1, PL 19543781, US 7, 232564 B2) for procedure of preparing phages against S. aureus and P. aeruginosa (P382800; US 20100227376 A1) and a method of obtaining bacteriophage preparations containing trace amounts of endotoxins owned by the Institute of Immunology and Experimental Therapy. EJ-M, MŁ, MŻ, MŁ-S, declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: bacteriophage isolation, therapeutic phages, experimental phage therapy, treatment of bacterial infections, antibiotic resistance

Citation: Weber-Dąbrowska B, Jończyk-Matysiak E, Żaczek M, Łobocka MB, Łusiak-Szelachowska M and Górski A (2016) Corrigendum: Bacteriophage Procurement for Therapeutic Purposes. Front. Microbiol. 7:1813. doi: 10.3389/fmicb.2016.01813

Received: 17 October 2016; Accepted: 28 October 2016;
Published: 09 November 2016.

Edited and reviewed by: Peter Mullany, University College London, UK

Copyright © 2016 Weber-Dąbrowska, Jończyk-Matysiak, Żaczek, Łobocka, Łusiak-Szelachowska and Górski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Beata Weber-Dąbrowska, weber@iitd.pan.wroc.pl